Navigation Links
Statin Therapy Cuts Bad Cholesterol Unprecedented 70 Percent

Research conducted at the Methodist DeBakey Heart Center in Houston shows that a combination statin therapy lowers bad cholesterol by an unprecedented// 70 percent, and has the added benefit of reducing life-threatening inflammation that can lead to heart disease and stroke.

The results published this week in the American Journal of Cardiology, also show 46 percent reduction in C-reactive protein (CRP), a marker for inflammation, in patients treated with 40 mg of rosuvastatin and 10 mg ezetimibe.

“A seventy percent drop is the largest reduction in bad cholesterol ever seen in a statin clinical trial. Cardiologists have long recognized the challenge in helping high-risk patients reach their target cholesterol levels, to ultimately prevent heart attack and stroke,” said Dr. Christie Ballantyne, cardiologist at the Methodist DeBakey Heart Center and principal investigator for the study. “These results offer hope for these patients.”

In addition, inflammation can lead to serious complications such as heart attack and stroke, and high levels of CRP can predict these risks years before they actually occur, Ballantyne said. Physicians have long relied on blood cholesterol as a key indicator of cardiovascular risk, but recent research suggests that high risk patients who achieved a low CRP level combined with a low LDL-c level had the fewest cardiovascular events.

“The highly effective reductions in both LDL-c and CRP seen in the EXPLORER study provide a new opportunity for high-risk patients to achieve optimal reduction in both factors with combination therapy,” Ballantyne said.

Key findings from EXPLORER** study:

* Crestor and Zetia reduced mean LDL-C by an unprecedented 70%.

* Significantly (p<0.001) more patients achieved their NCEP ATP III LDL-C goal of <100 mg/dL (94% vs. 79%) at six weeks with Crestor and Zetia compared with Crestor monotherapy.

* Crestor and Zetia reduc ed CRP levels by 46% compared with 29% with Crestor monotherapy.

* Both CRESTOR monotherapy and CRESTOR combined with ezetimibe produced similar increases in HDL-C (“good” cholesterol) (8.5% vs. 10.8%).

* CRESTOR and ezetimibe were both well tolerated.

** EXPLORER (Examination of Potential Lipid modifying effects Of Rosuvastatin in combination with Ezetimibe versus Rosuvastatin alone) was a 12-week, randomized trial of 469 patients with LDL-C 160-<250 mg/dL (4.1-<6.5 mmol/L) and coronary heart disease (CHD) or CHD risk equivalent designed to evaluate whether adding ezetimibe to CRESTOR would enable more patients with severely high cholesterol to achieve guideline lipid goals compared with CRESTOR monotherapy. Patients participated in a six-week dietary lead-in followed by six weeks of randomized treatment with rosuvastatin 40 mg alone or in combination with ezetimibe 10 mg.

Source-NewswiseBR>SRM
'"/>




Related medicine news :

1. Statins reduce heart attacks
2. Statins reduce risks for angioplasty patients
3. Statins Found To Be Helpful For Patients With Arthritis
4. Long-Term Benefits Of Statins Questioned
5. Higher Statin Dose Safely Reduces Stroke and Cardiac Arrest
6. Use of Statin can help in recovery from stroke
7. Statins Not Effective In Treating Calcific Aortic Stenosis
8. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
9. The Effects of Statins Questioned
10. Statins Taken For Reducing Cholesterol Found To Reduce Death Rate Associated With Heart Attack As Well
11. Study Finds No Link Between Statins And Breast Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
Breaking Medicine Technology: